London, June 24, 2024 (GLOBE NEWSWIRE) — June 24, 2024, London, UK – OPEN Health, a pre-eminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting, today announced a partnership with fusion, an innovative artificial intelligence (AI) and machine learning (ML) solutions provider that will work exclusively with OPEN Health. This alliance will

London, June 24, 2024 (GLOBE NEWSWIRE) — June 24, 2024, London, UK – OPEN Health, a pre-eminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting, today announced a partnership with fusion, an innovative artificial intelligence (AI) and machine learning (ML) solutions provider that will work exclusively with OPEN Health. This alliance will

Acino gains commercial rights for EXBLIFEP® (cefepime/enmetazobactam) within the member states of the Gulf Cooperation Council (GCC) and South Africa. EXBLIFEP® has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of severe infections earlier in 2024. Saint-Louis, France and Weil

Acino gains commercial rights for EXBLIFEP® (cefepime/enmetazobactam) within the member states of the Gulf Cooperation Council (GCC) and South Africa. EXBLIFEP® has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) for the treatment of severe infections earlier in 2024. Saint-Louis, France and Weil